Correction to: Biologic Drug Quality Assurance to Optimize HER2+ Breast Cancer Treatment: Insights from Development of the Trastuzumab Biosimilar SB3.

Abstract

The article Biologic Drug Quality Assurance to Optimize HER2+ Breast Cancer Treatment: Insights from Development of the Trastuzumab Biosimilar SB3.

Full Text

Published version (

Free)

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Journal: Targeted oncology	Publication Date: Oct 20, 2020
Citations: 3	License type: cc-by-nc